Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright

HC Wainwright restated their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report issued on Thursday morning,Benzinga reports. They currently have a $75.00 price objective on the biotechnology company’s stock.

Other analysts also recently issued research reports about the company. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research note on Monday. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. Raymond James reaffirmed an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Finally, Guggenheim lifted their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $178.71.

Sarepta Therapeutics Trading Down 0.9 %

Shares of SRPT stock opened at $114.45 on Thursday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $10.93 billion, a price-to-earnings ratio of 91.56 and a beta of 0.77. Sarepta Therapeutics has a 12-month low of $102.15 and a 12-month high of $173.25. The stock’s 50-day moving average price is $122.81 and its 200-day moving average price is $127.50.

Insider Activity at Sarepta Therapeutics

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its holdings in shares of Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after purchasing an additional 543,143 shares during the last quarter. Wellington Management Group LLP increased its position in Sarepta Therapeutics by 32.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after buying an additional 665,087 shares in the last quarter. Geode Capital Management LLC raised its stake in Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after buying an additional 44,306 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Sarepta Therapeutics by 9.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock worth $94,148,000 after acquiring an additional 63,437 shares in the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in Sarepta Therapeutics in the third quarter worth about $79,425,000. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.